04-Jul-2019 | Zion Market Research
Zion Market Research has published a new report titled “Plasma Fractionation Market by Product (Albumin, Protease Inhibitors, Coagulation Factor Concentrates, Immunoglobulins, and Others), by Application (Immunology, Hematology, Neurology, Rheumatology, Pulmonology, and Others), and by End-User (Hospitals & Clinics, Clinical Research Laboratories, Medical and Academic Institutes, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 –2025”. According to the report, the global plasma fractionation market was approximately USD 22.6 billion in 2018 and is expected to generate around USD 36.8 billion by 2025, at a CAGR of around 7.2% between 2019 and 2025.
Plasma processing is a process to obtain pure components that can be further used for injection and transfusion. The Cohn process (also called cold ethanol fractionation) was developed by Edwin J. Cohn during World War II, which was a major breakthrough in the field of blood plasma fractionation. Plasma proteins have biomarkers which help in the detection of rare diseases. This serves many clinical purposes. Plasma contains an innumerable variety of proteins. Around 20 of these proteins serve to produce plasma products, which are used to cure severe plasma conditions.
Browse the full “Plasma Fractionation Market by Product (Albumin, Protease Inhibitors, Coagulation Factor Concentrates, Immunoglobulins, and Others), by Application (Immunology, Hematology, Neurology, Rheumatology, Pulmonology, and Others), and by End-User (Hospitals & Clinics, Clinical Research Laboratories, Medical and Academic Institutes, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 –2025” Report at https://www.zionmarketresearch.com/report/plasma-fractionation-market
The increased penetration of the global plasma fractionation market is largely due to the increased use of immunoglobulins and alpha-1-antitrypsin in areas of medicine and the consistent investments in medicine and R&D, which has resulted in cost-effective procedures. The global population has a significant proportion of aged people, who suffer from rare diseases that often require high plasma proteins. There are multiple centers to collect plasma that facilitates smooth treatment and also the subsequent development of the plasma fractionation market globally. There has been huge governments support for increasing awareness and availability of plasma-derived medicine products for therapeutic usage. Purification methods and chromatographic fractionation have been used for plasma fractionation, which has resulted in the development of plasma products, such as coagulation factors, protease inhibitors, albumin, and immunoglobulin. However, the affordability of plasma products may be a major concern for patients worldwide.
The plasma fractionation market is fragmented on the basis of product, application, and end-user. Based on product, the market is segmented into protease inhibitors, albumin, coagulation factor concentrates (factor IX, prothrombin complex concentrate, factor VIII, Von Willebrand factor, factor XIII, and fibrinogen concentrates), and immunoglobulins (subcutaneous immunoglobulin, intravenous immunoglobulin (IVIG), and other immunoglobulins), and others. The application segment is divided into immunology, hematology, neurology, rheumatology, pulmonology, and others. The end-user segment comprises clinical research laboratories, hospitals and clinics, medical and academic institutes, and others.
North America leads the extraction of plasma proteins and treatment of genetic and blood-related disorders, which makes it the global leader of the plasma fractionation market. The Asia Pacific region exhibits the highest potential to grow notably in the global plasma fractionation market in the years ahead. Increased disposable income, rising lifestyle-related disorders, growing healthcare expenditure, and escalating awareness about health disorders are driving the region’s plasma fractionation market. Additionally, the increasing aging population and cancer prevalence are further driving the plasma fractionation market in the Asia Pacific region.
Some key players operating in the global plasma fractionation market are Green Cross, Biotest, Octapharma, LFB, Japan Blood Products, China Biologic Products, CSL, Shanghai RAAS Blood, Kedrion, and BPL.
This report segments the global plasma fractionation market into:
Plasma Fractionation Market: By Product
Plasma Fractionation Market: By Application
Plasma Fractionation Market: By End-User
Global Plasma Fractionation Market: By Region
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651